Sorin gets Committee for Proprietary Medicinal Products (CPMP) approval for TecneMAB:
This article was originally published in Clinica
Executive Summary
Sorin Biomedica's malignant melanoma imaging agent TecneMAB has been approved by the European Committee for Proprietary Medicinal Products. Although the decision was made on May 23rd it normally takes about two months for companies to receive written permission to begin marketing controlled products. Sorin, which is based in Saluggia, Italy, developed the technetium-99-labelled antibody in the mid-1980s.